Detection of anticardiolipin antibody in systemic lupus erythematosus and its clinical significance

2002 ◽  
Vol 1 (2) ◽  
pp. 107-108
Author(s):  
Hong Liang ◽  
Shizheng Xu ◽  
Xinfang Zhou ◽  
Layuan Xiong
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Significance ◽  
Lupus Erythematosus ◽  
Anticardiolipin Antibody ◽  
Systemic Lupus

scholarly journals Distribution and Clinical Significance of Lupus Anticoagulant and Anticardiolipin Antibody in 349 Patients with Systemic Lupus Erythematosus.

1992 ◽  
Vol 31 (2) ◽  
pp. 194-199 ◽  
Author(s):  
Chiho NINOMIYA ◽  
Osamu Taniguchi ◽  
Toshihiko KATO ◽  
Takao HIRANO ◽  
Hiroshi HASHIMOTO ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Significance ◽  
Lupus Erythematosus ◽  
Lupus Anticoagulant ◽  
Anticardiolipin Antibody ◽  
Systemic Lupus

scholarly journals The Expression and Clinical Significance of Different Forms of Mer Receptor Tyrosine Kinase in Systemic Lupus Erythematosus

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Huaqun Zhu ◽  
Xiaolin Sun ◽  
Lei Zhu ◽  
Fanlei Hu ◽  
Lianjie Shi ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Clinical Significance ◽  
Receptor Tyrosine Kinase ◽  
Lupus Erythematosus ◽  
Healthy Subjects ◽  
Mrna Levels ◽  
Systemic Lupus ◽  
Real Time Quantitative Pcr ◽  
Cd163 Expression

Objective. To investigate the expression and clinical significance of trans-membrane MerTK (mMer) on circulating CD14+ monocytes/macrophages and soluble MerTK (sMer) levels in plasma in systemic lupus erythematosus (SLE).Method. 108 SLE patients and 42 healthy controls were recruited in this study. The expression of mMer on the surfaces of CD14+ monocytes/macrophages was evaluated by flow cytometry (FCM). The sMer levels were measured by ELISA. Real-time quantitative PCR was applied to evaluate the mRNA levels of MerTK and ADAM17.Results. Both mMer expression on CD14+ monocytes/macrophages and sMer levels in plasma significantly increased in SLE patients compared to healthy subjects. The frequency of anti-inflammatory MerTK expressing CD14+CD16+ monocytes decreased in SLE. mMer expression was positively correlated with CD163 expression on CD14+ cells. Both the mMer expression on CD14+ monocytes/macrophages and sMer levels in plasma were positively correlated with SLEDAI. Furthermore, more elevated mMer and sMer levels were found in patients with higher SLEDAI, presence of anti-SSA, anti-Sm autoantibodies, and lupus nephritis.Conclusion. Both mMer and sMer levels significantly increased in SLE and positively correlated with disease activity and severity. The upregulation of MerTK expression may serve as a biomarker of the disease activity and severity of SLE.

Clinical Significance of Autoantibodies in Systemic Lupus Erythematosus

Rheumatology ◽  
1994 ◽  
Vol 33 (12) ◽  
pp. 1202-1203 ◽  
Author(s):  
M. HIETARINTA ◽  
M. VIANDER ◽  
A. TOIVANEN ◽  
O. LASSILA
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Significance ◽  
Lupus Erythematosus ◽  
Systemic Lupus

scholarly journals AB0567 Clinical significance of the detection of hla-drb1 alleles in patients with systemic lupus erythematosus

2018 ◽  
Author(s):  
E. Belolipetskaia ◽  
I. Beliaeva ◽  
V. Mazurov ◽  
S. Lapin ◽  
O. Tkachenko ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Significance ◽  
Lupus Erythematosus ◽  
Systemic Lupus

Pyoderma Gangrenosum Mimicking Antiphospholipid Antibody Syndrome in a Child With Juvenile Systemic Lupus Erythematosus

2020 ◽  
Author(s):  
metin kaya gürgöze ◽  
Aslıhan Kara ◽  
Mehmet yusuf sarı ◽  
İlknur Çalık ◽  
Saadet Akarsu
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Skin Biopsy ◽  
Pyoderma Gangrenosum ◽  
Lupus Erythematosus ◽  
Anticoagulation Therapy ◽  
Anticardiolipin Antibody ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Systemic Lupus ◽  
History Of

Abstract Background: Although pyoderma gangrenosum (PG) -like lesions have been rarely described in adults with the antiphospholipid antibody syndrome (APS) and systemic lupus erythematosus (SLE), the occurrence of PG as a preceding manifestation of APS in children with SLE has not been reported until. We present a young girl with SLE and APS who developed progressive extstensive ulcerations that were consistent with PG.Case presentation: A 14-year-old girl with a 2-year history of SLE was admitted to our department, complaining painful crusted ulcerations on her legs. Skin biopsy was reported as PG. However, she did not respond to immunosuppressive therapy administered. When her skin biopsy findings is reassessed in keeping with the positive anticardiolipin antibody results, superficial small vessel microthrombosis was observed. Diagnosis of APS and PG developing secondary to SLE were made. It was resulted in marked clinical improvement with anticoagulation therapy in addition to immunosuppressives as is recommended in APS. Conclusions: Based in clinical, pathological and response to proposed treatment, we can state that PG -like lesions in children with SLE could be considered as a secondary form of APS.

Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus

1997 ◽  
Vol 54 (3) ◽  
pp. 209-213 ◽  
Author(s):  
Junichi Kaburaki ◽  
Masataka Kuwana ◽  
Mihoko Yamamoto ◽  
Shinichi Kawai ◽  
Yasuo Ikeda
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Significance ◽  
Lupus Erythematosus ◽  
Annexin V ◽  
Systemic Lupus

scholarly journals Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction

2012 ◽  
Vol 2012 ◽  
pp. 1-12 ◽  
Author(s):  
Atiya Dhala
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Lupus Erythematosus ◽  
Connective Tissue Diseases ◽  
Anticardiolipin Antibody ◽  
Current Status ◽  
Systemic Lupus ◽  
Right Heart ◽  
Pulmonary Arterial

Pulmonary arterial hypertension (PAH) is commonly associated with connective tissue diseases (CTDs) including systemic sclerosis and systemic lupus erythematosus (SLE). The prevalence of PAH in SLE is estimated to be 0.5% to 17.5%. The pathophysiology of PAH involves multiple mechanisms from vasculitis andin-situthrombosis to interstitial pulmonary fibrosis which increases pulmonary vascular resistance, potentially leading to right heart failure. Immune and inflammatory mechanisms may play a significant role in the pathogenesis or progression of PAH in patients with CTDs, establishing a role for anti-inflammatory and immunosuppressive therapies. The leading predictors of PAH in SLE are Raynaud phenomenon, anti-U1RNP antibody, and anticardiolipin antibody positivity. The first-line of diagnostic testing for patients with suspected SLE-associated PAH (SLE-aPAH) involves obtaining a Doppler echocardiogram. Once the diagnosis is confirmed by right heart catheterization, SLE-aPAH patients are generally treated with oxygen, anticoagulants, and vasodilators. Although the prognosis and therapeutic responsiveness of these patients have improved with the addition of intensive immunosuppressive therapies, these treatments are still largely unproven. Recent data put the one-year survival rate for SLE-aPAH patients at 94%. Pregnant women are most at risk of dying due to undiagnosed SLE-aPAH, and screening should be considered essential in this population.

Sign in / Sign up

Export Citation Format

Share Document